Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics sold by majority-owned joint venture ViiV Healthcare, which helped group ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed £40 billion by 2031, up from £38 billion. The revision reflects confidence in its expanding specialty ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

They are solving some of the current challenges in cybersecurity and imaging to protect people and organizations. Through research, RIT is making an impact. RIT is one of the top universities in the ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier ...

GSK plc (LSE/NYSE ... is based on the promising results from the SWIFT and ANCHOR clinical trials. If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing ...

Correspondence to Dr Thomas Bandholm, Dept of Clinical Research, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre DK-2650, Denmark; thomas.quaade.bandholm{at}regionh.dk The REPORT guide ...

GSK plc has announced that new ... In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key ...